(Q36231510)

English

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection (English)

1 reference

Europe PubMed Central

12 August 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

object named as

Alex Mann

6

0 references

8

object named as

John S Oxford

1 reference

Europe PubMed Central

12 August 2017

Robert Lambkin-Williams

1

object named as

Rob Lambkin-Williams

1 reference

Europe PubMed Central

12 August 2017

Richard K. Broughton

3

object named as

Richard Broughton

1 reference

Europe PubMed Central

12 August 2017

author name string

Colin Gelder

2

1 reference

Europe PubMed Central

12 August 2017

Corey P Mallett

4

1 reference

Europe PubMed Central

12 August 2017

Anthony S Gilbert

5

1 reference

Europe PubMed Central

12 August 2017

David He

7

1 reference

Europe PubMed Central

12 August 2017

David Burt

9

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

22 December 2016

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

11

1 reference

Europe PubMed Central

12 August 2017

12

1 reference

Europe PubMed Central

12 August 2017

e0163089

1 reference

Europe PubMed Central

12 August 2017

copyright license

Creative Commons Attribution 4.0 International

22 December 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Mucosal immunity and nasal influenza vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Correlates of vaccine protection from influenza and its complications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Viral load drives disease in humans experimentally infected with respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

A plant-produced influenza subunit vaccine protects ferrets against virus challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

New approaches to influenza chemotherapy. Neuraminidase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

1 October 2017

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

22 September 2018

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

22 September 2018

Immune correlates of protection against influenza in the human challenge model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

22 September 2018

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

22 September 2018

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5179046

22 September 2018

Prevention and Control of Seasonal Influenza with Vaccines

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0163089

21 January 2018

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0163089

21 January 2018

Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/28005959

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0163089

1 reference

Europe PubMed Central

12 August 2017

2016PLoSO..1163089L

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36231510&oldid=2121886833"